Company intelligence / Profile preview

Interon Laboratories

Boston, Massachusetts, United Statesinteronlabs.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Interon Laboratories develops a novel class of immunotherapies—neuro-immunotherapies—by leveraging the interplay between the nervous and immune systems. Their proprietary technology aims to treat neurological and immune-related diseases with both biologic and small molecule approaches. The company’s scientific founders have published foundational work in top journals, including Nature. Lead programs are focused on autism spectrum disorder and related neuroinflammatory conditions; however, all available data suggest these are still at preclinical or early clinical stages.

Therapeutic areas: ImmunologyPsychiatryNeurology
Modalities: BiologicsSmall moleculesNeuro-immunotherapy
Industry: Biotech

Partnerships

HanAll Biopharma

Beyond the preview

Go deeper on Interon Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interon Laboratories.

Explore the full profile